RenovoRx Inc (RNXT) USD0.0001
- Add to watchlist
- This stock can be held in a
Business summary
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in delivering its targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. The Company’s therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) utilizes chemotherapeutics. RenovoTAMP combines its patented delivery system, RenovoCath, with small molecule chemotherapeutic agents, which can be forced across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. Its first product candidate, RenovoGem, is a drug /device combination consisting of intra-arterial gemcitabine and RenovoCath. RenovoGem has been developed for the treatment of two rare diseases: pancreatic cancer and cholangiocarcinoma (CCA). It has completed the first of two planned interim analyses of the ongoing open-label Phase III TIGeR-PaC clinical trial.
Contact details
Important dates
General stock information
- Short code:
- RNXT
- ISIN:
- US75989R1077
- Market cap:
- $14.76 million
- Shares in issue:
- 10.69 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.